Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market.

A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna .

The US Patent Trial and Appeal Board handed a massive victory to Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) on Wednesday, ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

MRNA’s Court Victory A German court ruled that BioNTech (BNTX) and Pfizer (PFE) have to pay Moderna damages because they infringed on Moderna’s mRNA patents. The court ordered BNTX and PFE to ...

The court said Pfizer and BioNTech would have to provide information on earnings derived from the use of the patent and that ...

After finding support at $30, Moderna (MRNA) added nearly $5.00 to close at $35.21. The firm participated in TD Cowen’s ...